Pfizer's maternal vaccine, sold as Abrysvo, and Sanofi and AstraZeneca's antibody shot, Beyfortus, are available in the ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

For a broader group of infants—0 to 7 months old—RSV-NET showed a 43 percent drop in hospitalizations in the 2024–2025 RSV season, and NVSN saw a 28 percent drop. Again, when Houston was excluded from ...

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is ...

New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...